Investors
Quarterly Reports
Q2 2019 Report
Monday, 19 AugustFjordalleen 16, 5. floor, Aker Brygge, OsloThe webcast will be streamed LIVE and the recording will be available after LIVE session is finished.
Link to live webcastScientific Presentations
EHA 24, Hellesøy et al
June 13 - 16 2019Amsterdam, Netherlands
Single Cell Signaling Pharmacodynamics in a Phase 1b Clinical Trial of the AXL inhibitor bemcentinib in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Read More
Annual Report 2018
BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.
Our annual report
Jonas Lies vei 91, 5009 Bergen, Norway
+ 47 559 61 159